A-Alpha Bio

AalphaBio operates in the biotechnology sector, focusing on the discovery and optimization of biologics, which are therapeutic proteins used to treat diseases. The company serves pharmaceutical and biotech firms looking to develop new drugs with high specificity and efficacy. AalphaBio's core business model revolves around its proprietary platform that can rapidly and quantitatively measure millions of protein-protein binding affinities, allowing for the characterization of library binding to many targets simultaneously. This platform is particularly useful for screening antagonists against full interaction networks and discovering biologics with defined specificity to multiple targets. The company generates revenue through service contracts, licensing agreements, and collaborative partnerships with other biotech and pharmaceutical companies. AalphaBio has been recognized as one of the 50 digital tech companies poised for greatness and has received a National Science Foundation SBIR grant to further develop its technology.

Keywords: biologics, protein-protein binding, drug discovery, biotechnology, pharmaceutical, specificity, affinity, screening, interaction networks, SBIR grant.